Westend Capital Management’s AbbVie ABBV Stock Holding History

Westend Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.77K	Sell	15 -112	-88%	-$24.1K	﹤0.01%	189
2026 Q1	$27.6K	Hold	127	–	–	0.01%	112
2025 Q4	$29K	Buy	+127	New	+$28.9K	0.01%	105
2025 Q3	–	Sell	-10,530	Closed	-$1.95M	–	254
2025 Q2	$1.95M	Sell	10,530 -599	-5%	-$111K	0.6%	24
2025 Q1	$2.33M	Buy	11,129 +11,097	+34,678%	+$2.16M	0.89%	23
2024 Q4	$5.69K	Hold	32	–	–	﹤0.01%	154
2024 Q3	$6.32K	Hold	32	–	–	﹤0.01%	153
2024 Q2	$5.45K	Sell	32 -53	-62%	-$8.78K	﹤0.01%	136
2024 Q1	$15.5K	Buy	+85	New	+$14.6K	0.01%	103
2016 Q2	–	Sell	-5,675	Closed	-$324K	–	65
2016 Q1	$324K	Buy	5,675 +1,585	+39%	+$88.3K	0.44%	46
2015 Q4	$242K	Sell	4,090 -1,675	-29%	-$96.5K	0.33%	51
2015 Q3	$326K	Buy	5,765 +665	+13%	+$43.3K	0.41%	49
2015 Q2	$347K	Buy	5,100 +645	+14%	+$42.1K	0.4%	49
2015 Q1	$274K	Buy	4,455 +2,130	+92%	+$129K	0.32%	53
2014 Q4	$152K	Buy	2,325 +1,975	+564%	+$125K	0.18%	51
2014 Q3	$19K	Buy	+350	New	+$19.4K	0.02%	71
2014 Q1	–	Sell	-350	Closed	-$18K	–	49
2013 Q4	$18K	Buy	+350	New	+$17.2K	0.02%	77
2013 Q2	$14K	Buy	+350	New	+$15.3K	0.01%	87

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Westend Capital Management's ABBV Position: Q2 2026 in Review

Westend Capital Management reduced its AbbVie (ABBV) stake by 88% in Q2 2026, selling an estimated $24.1K and leaving 15 shares worth $3.77K. The position accounts for ﹤0.01% of the portfolio, ranked #189.

Westend Capital Management first reported a position in ABBV in Q2 2013 and has held it in 18 quarters since. The position peaked at $2.33M in Q1 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Westend Capital Management held 15 shares of AbbVie worth $3.77K as of Q2 2026.
Westend Capital Management sold 112 AbbVie shares in Q2 2026, an estimated $24.1K.
AbbVie made up ﹤0.01% of Westend Capital Management's portfolio in Q2 2026, its #189 holding.
Westend Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 18 quarters since.
Westend Capital Management's AbbVie position peaked at $2.33M in Q1 2025.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Westend Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.